<DOC>
	<DOCNO>NCT01638013</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy long-term administration ASP015K patient complete Phase IIb Phase III study .</brief_summary>
	<brief_title>A Study Continue ASP015K Treatment Rheumatoid Arthritis Patients Who Completed Phase IIb Study Phase III Study ASP015K</brief_title>
	<detailed_description>This study extension study conduct open-label multicenter study rheumatoid arthritis ( RA ) patient complete Phase IIb Study ASP015K [ 015K-CL-RAJ1 ( hereinafter refer study RAJ1 ) ] , Phase III Study ASP015K [ 015K-CL-RAJ3 ( RAJ3 ) ] , Phase III Study ASP015K [ 015K-CL-RAJ4 ( RAJ4 ) ] . Patients receive oral ASP015K daily ( QD ) breakfast . The ASP015K dose increase later subject safety problem show lack efficacy . The duration treatment study drug differ depend upon subject .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subject complete treatment study drug study RAJ1 , RAJ3 RAJ4 specify protocol The subject himself/herself wish continue take study drug , investigator subinvestigator deem continued administration necessary appropriate Subject develop adverse reaction study drug study RAJ1 , RAJ3 RAJ4 , risk continue treatment drug expect outweigh benefit There abnormal finding xray take Week 0 , acute chronic infection , tuberculosis infection , malignancy suspect Hepatitis B virus hepatitis C virus carrier history positive test human immunodeficiency virus ( HIV ) infection Subject concurrent autoimmune disease ( except Sjogren 's syndrome ) RA history Subject clinically significant infection disease ( require hospitalization parenteral therapy ) Subject QTc &lt; 300 msec ECG measurement perform study site Week 52 study RAJ3 RAJ4 QTc &lt; 300 msec retest .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>ASP015K</keyword>
</DOC>